3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Pseudomyxoma Peritonei
1
Interventions
Specimen Handling
128
Magnetic Resonance Spectroscopy
105
Biopsy
76
pembrolizumab
63
Nivolumab
60
Carboplatin
59
Cisplatin
57
Cyclophosphamide
53
Paclitaxel
44
Radiotherapy
36
Bevacizumab
36
Gemcitabine
34
Dexamethasone
33
Rituximab
26
Doxorubicin
26
olaparib
25
Pemetrexed
25
Fluorouracil
25
atezolizumab
24
Radiation
24
Injections
23
Docetaxel
23
fludarabine
22
durvalumab
22
Vincristine
21
Prednisone
21
Oxaliplatin
21
Ipilimumab
21
Cytarabine
21
venetoclax
20
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Alemtuzumab
×
30 days
×
Clear all
NCT06084780
2026-06-05
TRANSCAPE
Case Comprehensive Cancer Center
Phase 2
Not yet recruiting
20 enrolled